SCHEMBL4291737

SCHEMBL4291737

O=C(CN1CCNCC1)Nc1ccc2c(c1)C(=O)c1cc(NC(=O)CN3CCNCC3)ccc1C2=O

nearest known ligand 0.59

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TERT O14746 15/20 0.59
ALDH1A1 P00352 1/20 0.57
MAPT P10636 1/20 0.57
NPY5R Q15761 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4297878 0.87 TERT (0.75) TERTALDH1A1MAPT
SCHEMBL4302435 0.87 TERT (0.79) TERTALDH1A1MAPT
SCHEMBL4299285 0.86 TERT (0.76) TERTALDH1A1MAPT
SCHEMBL4289287 0.84 TERT (0.74) TERTALDH1A1MAPT
SCHEMBL9630438 0.84 ALDH1A1 (0.64) TERTALDH1A1
SCHEMBL9630688 0.84 TERT (0.74) TERTALDH1A1MAPT
SCHEMBL9629545 0.81 SMN1; SMN2 (0.65) ALDH1A1MAPT
SCHEMBL7278718 0.79 ALDH1A1 (0.62) ALDH1A1
SCHEMBL12964242 0.77 ALDH1A1 (0.62) ALDH1A1
SCHEMBL7278994 0.77 SMN1; SMN2 (0.73) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES TERT, NAT10, POT1 TERT 1/4885ALDH1A1 481/4885MAPT 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.